Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Filana Therapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 0.70 · gapped above the open, then crossed back over prior close. High/low 0.73 at 5:45 am ET, 0.68 at 11:45 am ET.
Filana Therapeutics, Inc. has 7 disclosed suppliers and 0 disclosed customers. Each one is named in an SEC filing, either Filana Therapeutics, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
No filing we have read names a customer of Filana Therapeutics, Inc.. Customers appear here when Filana Therapeutics, Inc. names them, or when a company names Filana Therapeutics, Inc. as a supplier in its own annual report.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“This study was funded in part by a research grant award from NIH.”
FILING10-K0001437749-26-007962cik 0001069530
“In 2021, we entered into an agreement with Evonik Corporation to supply clinical-grade quantities of drug substance for simufilam.”
FILING10-K0001437749-26-007962cik 0001069530
“We have a drug supply agreement with Evonik Industries AG for simufilam.”
FILING10-K0001437749-26-007962cik 0001069530
“In addition to our owned intellectual property, on February 26, 2025, we entered into a License Agreement (the "License Agreement") with Yale University ("Yale") pursuant to which we were granted exclusive worldwide rights, with rights to sublicense, to Yale's interest in certain patent and other intellectual property rights that could be useful or necessary to the development and commercialization of simufilam for the treatment of TSC‑related epilepsy and other potential indications.”
FILING10-K0001437749-26-007962cik 0001069530
“The study was conducted by PsychoGenics, Inc., the TSC Preclinical Consortium's research partner.”
FILING10-K0001437749-26-007962cik 0001069530
“The study was conducted in collaboration with the TSCA and the TSC Preclinical Consortium using an animal model of TSC-related epilepsy, the Tsc1 conditional knockout (CKO) mouse line ( Tsc1 -CKO).”
FILING10-K0001437749-26-007962cik 0001069530
“The study was conducted in collaboration with the TSCA and the TSC Preclinical Consortium using an animal model of TSC-related epilepsy, the Tsc1 conditional knockout (CKO) mouse line ( Tsc1 -CKO).”
FILING10-K0001437749-26-007962cik 0001069530
Watchlist prices, news filtered to it, and its next report on your desk.
FLNA (Filana Therapeutics, Inc.) has 7 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.